would launch an oncology research and development (R&D) centre in Macul, Chile, in 2015. In November 2014, Pfizer Inc. announced that it has entered into an agreement with Merck KGaA, Darmstadt, Germany, to jointly develop and commercialize MSB0010718C, an investigational anti-PD-L1 antibody in development by Merck KGaA as a potential treatment for multiple types of cancer. In December 2014, iTeos Therapeutics SA announced a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3-dioxygenase (IDO1) and Tryptophan 2,3-dioxygenase (TDO2). History Pfizer Inc. was founded in 1849. The company was incorporated under the laws of the state of Delaware in 1942.
pfizer inc (PFE:SIX Swiss Exchange)
235 East 42nd Street
New York, NY 10017
|3M Co||$165.48 USD||+0.18|
|Bayer AG||€114.01 EUR||-1.39|
|Gilead Sciences Inc||$108.45 USD||+2.91|
|Novartis AG||SFr.93.05 CHF||+0.95|
|Procter & Gamble Co/The||$92.05 USD||+0.05|
|View Industry Companies|
Sponsored Financial Commentaries
To contact PFIZER INC, please visit www.pfizer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.